Soligenix, Inc. (SNGX): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of SNGX were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No SNGX insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SNGX short interest
Low short interest. 0.3% of SNGX shares are sold short: about 1 share in 352. Over the last 12 reports the number of shares short went down 90%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 66,373 SNGX shares were sold short, 0.3% of the shares outstanding, down 59.3% from the report before. At the average daily volume of 90,729 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 66,373 | 0.28% | -59% | 90,729 | 1.0 |
| Oct 15, 2026 | 162,935 | 0.75% | -3% | 128,548 | 1.3 |
| Sep 30, 2026 | 168,052 | 0.77% | -17% | 309,467 | 1.0 |
| Sep 15, 2026 | 202,558 | 0.93% | -4% | 128,360 | 1.6 |
| Aug 31, 2026 | 210,537 | 0.97% | +1% | 311,871 | 1.0 |
| Aug 14, 2026 | 207,637 | 0.95% | -65% | 171,039 | 1.2 |
| Jul 31, 2026 | 585,019 | 2.69% | +21% | 320,755 | 1.8 |
| Jul 15, 2026 | 483,436 | 4.69% | +18% | 445,198 | 1.1 |
| Jun 30, 2026 | 409,414 | 3.97% | -15% | 728,951 | 1.0 |
| Jun 15, 2026 | 479,055 | 4.65% | -93% | 3.61M | 1.0 |
| May 29, 2026 | 6.51M | 63.21% | +837% | 42.54M | 1.0 |
| May 15, 2026 | 694,906 | 6.74% | -32% | 1.05M | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Soligenix company events
Soligenix filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (listing). The latest was on Sep 21, 2026.
- Sep 21, 2026AnnouncementSoligenix, Inc. filed a prospectus supplement to increase the maximum aggregate offering amount of the shares of the Company’s common stock, par value $0.001 per share, issuable under the At Market Issuance Sales Agreement, dated January 23, 2026, with Rodman & Renshaw LLC, by an additional… Filing
- Jun 26, 2026AnnouncementSoligenix, Inc. filed a prospectus supplement to increase the maximum aggregate offering amount of the shares of the Company’s common stock, par value $0.001 per share, issuable under the At Market Issuance Sales Agreement, dated January 23, 2026, with Rodman & Renshaw LLC, by an additional… Filing
- Jun 12, 2026ListingSoligenix, Inc. received a written notice from the Listing Qualifications department of The Nasdaq Stock Market indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Filing
- May 28, 2026AnnouncementSoligenix, Inc. filed a prospectus supplement to increase the maximum aggregate offering amount of the shares of the Company’s common stock, par value $0.001 per share, issuable under the At Market Issuance Sales Agreement dated January 23, 2026 with Rodman & Renshaw LLC, by an additional aggregate… Filing
- Apr 28, 2026AnnouncementSoligenix, Inc. issued a press release announcing the interim results from the Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) trial evaluating HyBryte™ (Synthetic Hypericin) in the treatment of cutaneous T-cell lymphoma. Filing
- Feb 12, 2026AnnouncementSoligenix, Inc. issued a press release providing a shareholder update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber, detailing recent corporate progress, clinical developments across the Company’s pipeline, upcoming milestones, financing strategies and cash runway. Filing
- Jan 23, 2026AnnouncementSoligenix, Inc. and Rodman & Renshaw, LLC entered into an At Market Issuance Sales Agreement (as amended, the “Sales Agreement”), pursuant to which the Company may sell from time to time, at its option, shares of its common stock, par value $0.001 per share, having an aggregate offering price of up… Filing
- Nov 18, 2025ListingPreviously Disclosed Background As previously reported, on August 15, 2025, Soligenix, Inc. received a written notice from The Nasdaq Stock Market LLC advising the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Soligenix financials
Famous investors that hold SNGX
2 of the 50 well-known investors we track reported holding SNGX in their latest 13F filing. The largest position is Ken Griffin's, worth $227K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 628,136 | $227K | 0.0% | +200% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 44,900 | $16.3K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named SNGX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 2, 2026 | MJL Manager LLC | 13G/A | 9.4% |
| Nov 2, 2026 | MJL Manager LLC | 13G/A | 9.4% |
Questions about Soligenix, Inc. (SNGX) stock
Are SNGX insiders buying or selling?
No SNGX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in SNGX?
As of Oct 30, 2026, 66,373 SNGX shares were sold short, 0.3% of the shares outstanding, down 59.3% from the report before. At the average daily volume of 90,729 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold SNGX?
2 of the 50 well-known investors we track reported SNGX in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $227K. See all holders.
Executive pay
Soligenix's chief executive was paid a total of $1.1M for the year ended Dec 31, 2025, up 31% from $833K the year before. In the last 12 months, Soligenix's executives and directors bought no stock on the open market and sold none.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.